Apollo Therapeutics Ltd
Clinical trials sponsored by Apollo Therapeutics Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for tough blood cancers? early trial launches Results expected Mar 2027 (estimated)
- New hope for Hard-to-Treat cancers: APL-5125 enters human trials Results expected Apr 2027 (estimated)
- New vaccine aims to snuff out the common cold Results expected May 2027 (estimated)
- New drug APL-9796 tested for lung blood pressure disorder Results expected Aug 2027 (estimated)
-
New eczema drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema). About 280 participants will receive either the drug or a placebo to see if it reduces skin redness, thickness, and itching over 24 weeks. The goal is to find a saf…
Phase 2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for tough blood cancers? early trial launches
Disease control Recruiting nowThis early-stage study tests an experimental drug called APL-4098, alone or with standard treatments, in adults with acute myeloid leukemia (AML) or related blood disorders. The goal is to find a safe dose and see if it shrinks cancer. About 100 people will take part.
Phase 1 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug APL-9796 tested for lung blood pressure disorder
Disease control Recruiting nowThis Phase 2 trial tests an experimental drug called APL-9796 in 48 adults with pulmonary hypertension (high blood pressure in the lungs). The study aims to see if the drug is safe, tolerable, and effective. Participants receive injections under the skin, and researchers monitor …
Phase 2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC